Biotech, Pharma Industries To Target IP Protection Legislation, Patent Reform
By Liza Porteus Viana for Intellectual Property Watch
When the new administration and Congress come into office following the November elections in the United States, the pharmaceutical and biotechnology industries will prioritise protection of their intellectual property and innovative biological drugs as the push for cheaper, generic versions gets stronger. Patent reform also will continue to be a lobbying priority, as well as making sure intellectual property is protected in any forthcoming international trade agreements.
